$AVCO Recent Achievements Highlight Growth Opportunity
Link to full article: http://spotlightgrowth.com/index.php/2019/06/...portunity/
Avalon GloboCare Corp. (NASDAQ: AVCO) has seen some big developments since the beginning of June 2019. After a strong start to 2019, which was backed by a break-through discovery of the world’s first saliva-based exosome biomarker for use as a diagnostic and therapeutic target for oral cancer treatment. This announcement propelled AVCO to a 52-week high of $13.50. However, extensive profit-taking and shorting led to a reversal back around the trading range prior to the January discovery.
Despite the out-of-touch pullback, Avalon GloboCare has continued to make major operational developments and progress. Particularly through mid-June 2019, management has made a number of key announcements, which has helped the stock see a rebound in both share price and volume activity. Here is a detailed look at the major developments Avalon GloboCare has seen in recent weeks:
Corporate News Releases:
June 10th – Avalon’s first major announcement in June came after management disclosed achieving the major milestone of bio-production standardization for its clinical-grade, stem cell-derived exosomes. The pivotal milestone was made possible through the previously-announced co-development program with Weill Cornell Medicine and Dr. Yen-Michael Hsu. Following the announcement, Avalon noted it was in the planning stages for the commercial launch of a series of over-the-counter skincare and wound-healing products using the exosomes.
“We are pleased to complete such a significant developmental milestone of our exosome program,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare and Co-CEO of its subsidiary GenExosome Technologies. “As a result, we look forward to an accelerated pathway of our exosome-based clinical programs for regenerative therapeutics as well as exosome product commercialization,” added Dr. Jin.”
June 13th – The company announced plans to unveil further details on its commercialization plan for its exosome products at the Second Aesthetic Industry Conference, the largest aesthetics conference in Asia. Dr. Yu Zhou, the Co-CEO of Avalon subsidiary, GenExosome Technologies, provided the keynote address at the conference. In addition to the commercialization plan, Dr. Zhou led a session on the “Application of Stem Cell Exosomes” during the event.
“Avalon GloboCare is dedicated to assembling and integrating the premier scientific, clinical, and regulatory resources from around the world, in order to accelerate innovative and transformative cellular and exosome-based technologies, as well as their clinical applications,” stated Dr. Jin. “We are honored to lead a panel with international experts to discuss this evolving ecosystem, as well as showcasing our exosome product commercialization plan.”
June 18th – Avalon GloboCare details it is expected to be included in the Russell 3000 Index, after the annual Russell U.S. Index Reconstitution, which is scheduled to take place on June 28, 2019. This is a big deal for the company, as it will open the door to further institutional investor interest. Overall, there is approximately $9 trillion in assets that are benchmarked against various Russell U.S. indices.
“We look forward to our inclusion in the Russell 3000® Index, which we believe reflects our continued growth and the progress we are making at Avalon,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare. “Inclusion in the Russell 3000® Index is expected to benefit our Company and shareholders by elevating our exposure within the global investment community.”
Form 4 Filings: Insider Buying By Chairman Lu Wenzhao
Insider transactions disclosed through Form 4s can be important indicators for measuring management’s sentiment and outlook. Traditionally-speaking, insiders only purchase stock when they believe the market is under-valuing the company and they see greater potential for gains ahead. Insiders can sell for a variety of reasons, which can be a little more difficult to read in terms of corporate outlook. However, this is why insider buying is always something worth keeping an eye on.
For the purposes of Avalon GloboCare, Form 4s were filed on June 6th and 7th, which showed Chairman Lu Wenzhao had purchased a total of 36,000 shares of AVCO common stock. This represents an investment value of $70,230 over the two Form 4 filings.
An SEC Form 4 filing dated June 6, 2019 disclosed Avalon GloboCare Corp. Chairman Wenzhao had purchased 21,000 shares of AVCO at a price of $2.03 per share. This comes out to total investment value of $42,630.
On June 7, 2019, Avalon GloboCare filed an additional SEC Form 4, which showed Chairman Lu Wenzhao again buying up shares. In the second Form 4, Mr. Wenzhao purchased an additional 15,000 shares of AVCO at a price of $1.84. The latest insider purchase equates to total investment value of $27,600.
With the latest filing, Mr. Wenzhao holds current share total of roughly 25.94 million shares of AVCO common stock (along with the additional 2 million shares that were acquired in the private transaction).
AVCO: Shares Up Since June 6th Form 4 Filing, Weekly Volume Surges
Avalon’s strong first half of June can be easily seen in the stock price and volume compared to the last two weeks of May 2019. Since June 6, 2019, when the first Form 4 filing was released showing Chairman Wenzhao’s first purchase, AVCO has jumped 25.42%.
Furthermore, weekly volume has seen an incredible surge through the first two completed weeks of June 2019. Let’s break it down:
AVCO Weekly Volume For Week of 5/20/19 = 57,000 shares
AVCO Weekly Volume For Week of 5/27/19 = 84,200 shares
AVCO Weekly Volume For Week of 6/3/19 = 185,700 shares
AVCO Weekly Volume For Week of 6/10/19 = 183,480 shares
*Weekly volume and performance data courtesy of Barchart.com
The weekly volume data clearly shows increasing activity and since shares are up over 25% during that volume bump, it can be assumed that a majority of the volume was from buying activity. Furthermore, if we measured volume results from the week of 6/10 compared to the week of 5/27, you would see strong growth of 118%. Comparing volume difference between weeks of 6/3 and 5/20, the growth skyrockets an impressive 226%. Overall, Avalon GloboCare’s volume and share price growth through the first two weeks of June 2019 shows that a turnaround may be in the early stages.
AVCO: Weekly Chart Still Showing Deep Oversold Territory
Despite Avalon GloboCare shares’ recent rebound in June, the weekly charts continue to highlight and oversold state. AVCO’s weekly stochastics are currently at 11.31, far within the oversold territory of 20 or below. The relative strength index (RSI) is neither showing oversold nor overbought conditions, but at 40.29, it certainly is closer to the oversold threshold at 30.
Avalon’s moving average convergence divergence (MACD) histogram clearly shows the bottom is rounding off and beginning to angle higher. This is a positive sign, as it shows that bullish investors are slowly continuing to take control of the trend. Furthermore, with strong, long-term support at $2.00, Avalon looks like it is continuing to bottom out after such a over-the-top pullback.
Overall, Avalon GloboCare has had a lot of great developments to celebrate since the beginning of June, in particular. Major operational developments are beginning to give way to renewed investor demand and interest. Volume and AVCO share price have seen a strong rebound in the past several weeks and the weekly chart suggests that there is further rebound still to come. Avalon and its management team continues to make strong decisions guiding the company through its growth plan and into the future.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated twenty thousand dollars cash for the creation and dissemination of this content by INS Media to conduct investor relations on behalf of Avalon GloboCare. Avalon GloboCare has retained INS Media to provide investor relations services.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: http://spotlightgrowth.com/index.php/disclosures/
Link to full article: http://spotlightgrowth.com/index.php/2019/06/...portunity/
Avalon GloboCare Corp. (NASDAQ: AVCO) has seen some big developments since the beginning of June 2019. After a strong start to 2019, which was backed by a break-through discovery of the world’s first saliva-based exosome biomarker for use as a diagnostic and therapeutic target for oral cancer treatment. This announcement propelled AVCO to a 52-week high of $13.50. However, extensive profit-taking and shorting led to a reversal back around the trading range prior to the January discovery.
Despite the out-of-touch pullback, Avalon GloboCare has continued to make major operational developments and progress. Particularly through mid-June 2019, management has made a number of key announcements, which has helped the stock see a rebound in both share price and volume activity. Here is a detailed look at the major developments Avalon GloboCare has seen in recent weeks:
Corporate News Releases:
June 10th – Avalon’s first major announcement in June came after management disclosed achieving the major milestone of bio-production standardization for its clinical-grade, stem cell-derived exosomes. The pivotal milestone was made possible through the previously-announced co-development program with Weill Cornell Medicine and Dr. Yen-Michael Hsu. Following the announcement, Avalon noted it was in the planning stages for the commercial launch of a series of over-the-counter skincare and wound-healing products using the exosomes.
“We are pleased to complete such a significant developmental milestone of our exosome program,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare and Co-CEO of its subsidiary GenExosome Technologies. “As a result, we look forward to an accelerated pathway of our exosome-based clinical programs for regenerative therapeutics as well as exosome product commercialization,” added Dr. Jin.”
June 13th – The company announced plans to unveil further details on its commercialization plan for its exosome products at the Second Aesthetic Industry Conference, the largest aesthetics conference in Asia. Dr. Yu Zhou, the Co-CEO of Avalon subsidiary, GenExosome Technologies, provided the keynote address at the conference. In addition to the commercialization plan, Dr. Zhou led a session on the “Application of Stem Cell Exosomes” during the event.
“Avalon GloboCare is dedicated to assembling and integrating the premier scientific, clinical, and regulatory resources from around the world, in order to accelerate innovative and transformative cellular and exosome-based technologies, as well as their clinical applications,” stated Dr. Jin. “We are honored to lead a panel with international experts to discuss this evolving ecosystem, as well as showcasing our exosome product commercialization plan.”
June 18th – Avalon GloboCare details it is expected to be included in the Russell 3000 Index, after the annual Russell U.S. Index Reconstitution, which is scheduled to take place on June 28, 2019. This is a big deal for the company, as it will open the door to further institutional investor interest. Overall, there is approximately $9 trillion in assets that are benchmarked against various Russell U.S. indices.
“We look forward to our inclusion in the Russell 3000® Index, which we believe reflects our continued growth and the progress we are making at Avalon,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare. “Inclusion in the Russell 3000® Index is expected to benefit our Company and shareholders by elevating our exposure within the global investment community.”
Form 4 Filings: Insider Buying By Chairman Lu Wenzhao
Insider transactions disclosed through Form 4s can be important indicators for measuring management’s sentiment and outlook. Traditionally-speaking, insiders only purchase stock when they believe the market is under-valuing the company and they see greater potential for gains ahead. Insiders can sell for a variety of reasons, which can be a little more difficult to read in terms of corporate outlook. However, this is why insider buying is always something worth keeping an eye on.
For the purposes of Avalon GloboCare, Form 4s were filed on June 6th and 7th, which showed Chairman Lu Wenzhao had purchased a total of 36,000 shares of AVCO common stock. This represents an investment value of $70,230 over the two Form 4 filings.
An SEC Form 4 filing dated June 6, 2019 disclosed Avalon GloboCare Corp. Chairman Wenzhao had purchased 21,000 shares of AVCO at a price of $2.03 per share. This comes out to total investment value of $42,630.
On June 7, 2019, Avalon GloboCare filed an additional SEC Form 4, which showed Chairman Lu Wenzhao again buying up shares. In the second Form 4, Mr. Wenzhao purchased an additional 15,000 shares of AVCO at a price of $1.84. The latest insider purchase equates to total investment value of $27,600.
With the latest filing, Mr. Wenzhao holds current share total of roughly 25.94 million shares of AVCO common stock (along with the additional 2 million shares that were acquired in the private transaction).
AVCO: Shares Up Since June 6th Form 4 Filing, Weekly Volume Surges
Avalon’s strong first half of June can be easily seen in the stock price and volume compared to the last two weeks of May 2019. Since June 6, 2019, when the first Form 4 filing was released showing Chairman Wenzhao’s first purchase, AVCO has jumped 25.42%.
Furthermore, weekly volume has seen an incredible surge through the first two completed weeks of June 2019. Let’s break it down:
AVCO Weekly Volume For Week of 5/20/19 = 57,000 shares
AVCO Weekly Volume For Week of 5/27/19 = 84,200 shares
AVCO Weekly Volume For Week of 6/3/19 = 185,700 shares
AVCO Weekly Volume For Week of 6/10/19 = 183,480 shares
*Weekly volume and performance data courtesy of Barchart.com
The weekly volume data clearly shows increasing activity and since shares are up over 25% during that volume bump, it can be assumed that a majority of the volume was from buying activity. Furthermore, if we measured volume results from the week of 6/10 compared to the week of 5/27, you would see strong growth of 118%. Comparing volume difference between weeks of 6/3 and 5/20, the growth skyrockets an impressive 226%. Overall, Avalon GloboCare’s volume and share price growth through the first two weeks of June 2019 shows that a turnaround may be in the early stages.
AVCO: Weekly Chart Still Showing Deep Oversold Territory
Despite Avalon GloboCare shares’ recent rebound in June, the weekly charts continue to highlight and oversold state. AVCO’s weekly stochastics are currently at 11.31, far within the oversold territory of 20 or below. The relative strength index (RSI) is neither showing oversold nor overbought conditions, but at 40.29, it certainly is closer to the oversold threshold at 30.
Avalon’s moving average convergence divergence (MACD) histogram clearly shows the bottom is rounding off and beginning to angle higher. This is a positive sign, as it shows that bullish investors are slowly continuing to take control of the trend. Furthermore, with strong, long-term support at $2.00, Avalon looks like it is continuing to bottom out after such a over-the-top pullback.
Overall, Avalon GloboCare has had a lot of great developments to celebrate since the beginning of June, in particular. Major operational developments are beginning to give way to renewed investor demand and interest. Volume and AVCO share price have seen a strong rebound in the past several weeks and the weekly chart suggests that there is further rebound still to come. Avalon and its management team continues to make strong decisions guiding the company through its growth plan and into the future.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated twenty thousand dollars cash for the creation and dissemination of this content by INS Media to conduct investor relations on behalf of Avalon GloboCare. Avalon GloboCare has retained INS Media to provide investor relations services.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: http://spotlightgrowth.com/index.php/disclosures/
